Terms were not disclosed.
Exton, Pa.-based Morphotek, a subsidiary of Eisai Corp. of North America, said Synageva will use its proprietary Synageva Expression Platform.
Morphotek specializes in developing treatments for cancer, inflammation and infectious disease.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment